Following disappointing outcomes of BRAF inhibitor monotherapy in CRC, the trial protocol was amended to include the addition of EGFR inhibitors (specifically, vemurafenib combined with cetuximab) in the CRC cohort [93,94]. The gene discussed is EGFR; the disease is colorectal carcinoma.